Biotechs receive investment interest following AusBiotech 2011
28 October, 2011 by Staff WritersForeign investors have expressed interest in a number of Australian biotechnology companies following the AusBiotech 2011 conference last week.
ResMed profits dented by high Australian dollar
25 October, 2011 by Staff WritersResMed has posted a record quarterly revenue of $314.8 million, but an 11% decrease in net income due to the high Australian dollar.
Pharmaxis shares soar as Europe set to approve Bronchitol
24 October, 2011 by Staff WritersCystic fibrosis treatment, Bronchitol, has been recommended for approval in Europe, seeing Pharmaxis (ASX:PXS) shares jump by nearly 60 per cent.
Phosphagenics raises $24.1m to fund oxycodone patch trial
21 October, 2011 by Staff WritersAdditional $3 million to be raised in share purchase plan to fund clinical trials in anticipation of FDA registration in 2013.
Australian biotechs showcased at investment summit
19 October, 2011 by Staff WritersAustralia's top biotech companies are showing their wares to investors from around the world at the AusBiotech Australasian Life Sciences Investment Summit.
AusBiotech 2011: Healing touch
17 October, 2011 by Tim DeanAustralian labs are conducting pioneering research into tissue regeneration, such as the new treatment for severe burns, NovoSkin.
AusBiotech 2011: Dealing with the dragon
13 October, 2011 by Tim DeanThe growth of China’s life sciences sector presents tremendous opportunities for Australian biotechs, but it pays to understand the nuances of the culture and take things slow.
Going green: Life Scientist of the Year
12 October, 2011 by Tim DeanAssociate Professor Min Chen from The University of Sydney has been awarded the Prime Minister’s Prize for Life Scientist of the Year.
Into the pits: clathrin inhibiters licensed to UK biotech
11 October, 2011 by Tim DeanThe CMRI, University of Newcastle and Freie Universitaet Berlin have licensed their newly-developed clathrin inhibitors to Ascent Scientific in the UK.
Experimental DNA vaccine gives full protection against herpes
11 October, 2011 by Tim DeanCoridon has announced the results of a pre-clinical animal study of new DNA vaccine showing 100% protection against herpes simplex virus 2.
Feature: Small is big in drug delivery
07 October, 2011 by Fiona WylieGood things really do come in small packages, and they don't come much smaller than the nano-containers being developed by Frank Caruso's team in Melbourne.
Biotron kicks off trial of novel HIV treatment
05 October, 2011 by Staff WritersProof-of-concept human trial of HIV drug BIT225 has commenced, with results expected in the first quarter of 2012.
Mesoblast and Lonza partner to mass-produce stem cells
27 September, 2011 by Tim DeanLonza to manufacture commercial quantities of Mesoblast’s adult stem cells with an option for Mesoblast to buy purpose-built manufacturing facility.
Prana trial gains interest from Huntington’s disease community
16 September, 2011 by Staff WritersInternational Huntington's disease patients groups have expressed strong interest in upcoming phase II trials of Prana’s treatment.
HealthLinx makes a push into Chinese market
09 September, 2011 by Staff WritersHealthLinx has partnered with Chinese CRO with a vision to launching ovarian cancer treatment, OvPlex, into Chinese market.
